FindTrial
Sign In

A Randomized Controlled Clinical Trial of Yiqi Huoxue Decoction in Preventing Podocyte Injury in Early Diabetic Nephropathy

A Randomized Controlled Clinical Trial of Yiqi Huoxue Decoction in Preventing Podocyte Injury in Early Diabetic Nephropathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012589
Enrollment
Unknown
Registered
2017-09-05
Start date
2017-09-05
Completion date
Unknown
Last updated
2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

One:Yiqi Huoxue Decoction+Irbesartan Tablets
Two:Irbesartan Tablets

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients in our hosipital who meets the following requirements: 1. Meet the diagnostic criteria for diabetic nephropathy; Meet the diagnostic criteria for Qixuxueyu symptom; 30mg/d = urine microalbumin = 300mg/d; eGFR>60ml/min/1.73m2 (CKD stage1-stage; 2. ages between 18 years old and 75 years old.

Exclusion criteria

Exclusion criteria: 1. Type 1 Diabetes; 2. Patients who can not cooperate with us to take the medicines; 3. With other severe disease; 4. Allergic to our medicines or is in any other clinical drug trials or has been in any other clinical drug trials in the last three months; 5. eGFR=60ml/min/1.73m2.

Design outcomes

Primary

MeasureTime frame
24h urinary protein;podocalyxin;ACR;biochemical criterion;—

Countries

China

Contacts

Public ContactWang Niansong

Shanghai Sixth People's Hospital

wangniansong2012@126.com+86 18930177399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026